Elevated Hematocrit Requiring Polycythemia Vera Workup
These values meet WHO 2016 diagnostic criteria thresholds for polycythemia vera (PV) and mandate immediate evaluation with JAK2 mutation testing, regardless of patient sex. 1
Diagnostic Significance
The hematocrit of 49.4% exceeds the WHO 2016 major criterion threshold for PV diagnosis. Specifically:
- Men: Hct >49% or Hgb >16.5 g/dL
- Women: Hct >48% or Hgb >16 g/dL 1
Your patient's hemoglobin of 16 g/dL combined with Hct 49.4% triggers diagnostic evaluation regardless of whether this is a male or female patient, as the hematocrit alone meets male criteria and approaches female thresholds.
Immediate Workup Algorithm
Step 1: JAK2 Mutation Testing
- Order JAK2 V617F mutation analysis immediately 1
- This is the most critical initial test, as JAK2 mutations are present in >95% of PV cases
- Do not wait for other results before ordering this test 2
Step 2: Serum Erythropoietin Level
- Low EPO → suggests primary erythrocytosis (PV or other myeloproliferative neoplasm)
- Normal/elevated EPO → suggests secondary erythrocytosis 3
Step 3: Assess for Secondary Causes
- Iron studies (ferritin, iron saturation) - iron deficiency can mask PV 4
- Smoking history and carboxyhemoglobin level
- Sleep apnea screening
- Renal imaging if EPO elevated (renal tumors, cysts)
- Testosterone use history 5
Critical Diagnostic Considerations
Why This Matters for Morbidity/Mortality
PV carries significant thrombotic risk with potential for:
- Stroke
- Myocardial infarction
- Deep vein thrombosis/pulmonary embolism
- Portal vein thrombosis 6
- Progression to acute myeloid leukemia (1-2% risk)
Importantly, thrombotic events can occur even with "borderline" hematocrit elevations and may be the presenting feature before overt polycythemia develops 6. One case series documented JAK2-positive PV presenting with portal vein thrombosis despite completely normal hemoglobin and hematocrit 6.
Common Pitfalls to Avoid
Do not dismiss borderline elevations: The 2016 WHO criteria lowered diagnostic thresholds specifically because thrombotic complications occur at these levels 1. Studies show that 2.4% of men and 0.11% of women in the general population meet these new criteria 7, but this does not negate the need for evaluation when values are abnormal.
Do not assume iron deficiency excludes PV: Iron deficiency can mask PV by preventing the hemoglobin from rising further. The guidelines explicitly require iron replacement trials in iron-deficient patients to unmask occult PV 4, 1.
Do not rely solely on hematocrit for risk assessment: While elevated hematocrit triggers diagnosis, thrombotic risk in PV relates to multiple factors beyond viscosity, including platelet activation and leukocytosis 8. The presence of JAK2 mutations and other clonal markers drives thrombotic risk independent of hematocrit levels 8.
If JAK2 Positive: Complete PV Diagnostic Criteria
To confirm PV diagnosis when JAK2 is positive, you need 1:
Major Criteria (all 3 required):
- ✓ Hgb >16.5 g/dL (men) or >16 g/dL (women), OR Hct >49% (men) or >48% (women)
- Bone marrow biopsy showing hypercellularity with trilineage proliferation
- ✓ JAK2 mutation present
Minor Criterion:
- Subnormal serum erythropoietin level
Diagnosis requires all 3 major criteria OR the first 2 major criteria plus the minor criterion.
If JAK2 Negative
Consider:
- CALR or MPL mutations (rare in isolated erythrocytosis, more common in essential thrombocythemia)
- Secondary erythrocytosis causes
- Congenital erythrocytosis syndromes (especially if young patient or family history) 3
- Repeat testing in 3-6 months if clinical suspicion remains high
Urgent vs. Routine Evaluation
This requires urgent (within 1-2 weeks) but not emergent evaluation unless the patient has:
- Symptoms of hyperviscosity (headache, visual changes, dizziness)
- History of thrombosis
- Significant thrombocytosis or leukocytosis on the same CBC
The RBC count of 5.56 ×10⁶/µL is elevated and supports the erythrocytosis, making this a true polycythemia rather than spurious elevation from dehydration.